TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00795002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04431349

Intervention type: DRUG
Intervention: Ticagrelor 180mg
Description: Patient received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
Study: NCT00683514

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
Description: q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
Description: q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)
Description: q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1
Study: NCT03074097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
Study: NCT04431349

Intervention type: DRUG
Intervention: Clopidogrel 75mg
Description: Patient received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
Study: NCT02428309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Study: NCT03194880

Intervention type: DEVICE
Intervention: AlereCOMBO and Alere q Detect
Description: The feasibility assessment will comprise of two components:~1. User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~2. The laboratory component: For each test we will evaluate:~   * The percentage of assays completed~  * The percentage of assays incomplete (i.e. invalid result on two attempts)~  * Reasons for incomplete assays, e.g.~     * The sample could not be delivered to the strip or cartridge correctly~    * Invalid control~    * Results could not be interpreted~    * Others
Study: NCT02787135

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: emotion-oriented Cognitive Behavior Therapy
Description: Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: emotion-oriented Cognitive Behavior Therapy
Description: Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
Study: NCT03162523

Intervention type: RADIATION
Intervention: High-Dose Rate Brachytherapy

Intervention type: RADIATION
Intervention: High-Dose Rate Brachytherapy
Study: NCT02950051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d
Study: NCT04139239

Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-revision
Description: Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
Study: NCT03623399

Intervention type: PROCEDURE
Group type: OTHER
Intervention: low gas pressure laparoscopy
Description: To apply different CO2 entrance and intraoperative pressures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: low gas pressure laparoscopy
Description: To apply different CO2 entrance and intraoperative pressures
Study: NCT04397497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavrilimumab
Description: human monoclonal antibody targeting GM-CSF receptor-alpha

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching volume of diluent
Study: NCT03770754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Control group
Description: For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Control group
Description: For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Control group
Description: For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleand and shape Group 1
Description: For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleand and shape Group 1
Description: For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleand and shape Group 1
Description: For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Group 2
Description: For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Group 2
Description: For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Group 2
Description: For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered
Study: NCT02523508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Passive limb mobilization which did not involve the spine
Study: NCT02609971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration at 50 Hz
Description: During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
Study: NCT03704025

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current guidelines rehabilitation
Description: Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
Study: NCT02950051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d
Study: NCT01611701

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryoballoon ablation
Description: In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s.
Study: NCT03254082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response of F-1000
Description: The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to sumac sorghum flour
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to MMR sorghum flour
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to wheat flour
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycemic response to sucrose
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
Study: NCT05420155

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical treatment of hepatic hydatidic cyst
Study: NCT02111590

Intervention type: DRUG
Intervention: Immunoglobulins
Description: SCIG dosage is individualized for each patient according to previous IVIG dosage

Intervention type: DRUG
Intervention: Immunoglobulins
Description: SCIG dosage is individualized for each patient according to previous IVIG dosage
Study: NCT00959933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol 200 Capsules (Schering Corporation, U.S.A.)
Study: NCT02897713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive enteral nutrition
Description: After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine enteral nutrition
Description: Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
Study: NCT01339585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
Study: NCT02863926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of cBMA aspirate into the index leg
Description: Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of cBMA aspirate into the index leg
Description: Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of cBMA aspirate into the index leg
Description: Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
Study: NCT04546308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Eight weeks whole-body resistance exercise training (80%1 repetition maximal, 3 sessions per week) followed by a 4-week detraining intervention
Study: NCT00605293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120, 200 or 360 micrograms iv/month (starting dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: As prescribed
Study: NCT01404520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise based multimodal intervention
Description: The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
Study: NCT02852551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAT-1251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAT-1251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01043770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group lifestyle education
Description: Structured group education programme based on lifestyle changes (dietary and increased physical activity)
Study: NCT02019160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% AgNO3 solution followed by 5% NaF varnish
Description: Dosage of 4.4μg±1.4μg fluoride per use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 38% SDF solution followed by placebo varnish
Description: Dosage of 8.8μg±2.8μg fluoride per use
Study: NCT03807765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg intravenous Nivolumab administered every 4 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy.
Study: NCT00454051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
Study: NCT02025881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + etoposide
Description: Carboplatin 160 mg/m\^2 Day 1 to day 5, as an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m\^2 D ay 1 to day 5, as an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 200 mg/m² Day-3 to day-1, as an intravenously infusion over 1 hour dilution in 200 ml/m\^2 of 5% glucose saline or sodium chloride 9 mg/ml (0.9%).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Busilvex
Description: Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -\> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -\> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -\> 3.52 mg/kg/day; \> 23 à 34 kgs 0.76 mg/kg/dose -\> 3.04 mg/kg/day; \> 34 kgs -\> 0.64 mg/kg/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolimide + Irinotecan
Description: During 2 cycles of 21 days:~* Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;~* Irinotecan: 10 mg/m\^2/day IV from Day 1 to Day 5 + from Day 8 to Day 12

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Etoposide + radiotherapy
Description: * Etoposide: 35 mg/m\^2/day PO during 21days~* Radiotherapy: 1.8 Gy/fraction/day (total dose: 54 Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m\^2/day PO during 5 days, during 6 cycles of 21 days
Study: NCT03529474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychology and Physiotherapy group
Description: Psychological program: 4 sessions,2 hours each,4 months~* Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~* Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~* Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~* Aerobic exercise:walking, cycling~* Warm-up: active ROM exercises of inferior and superior extremities (ISE)~* Progressive resistance training with elastic bands of ISE~* Stretching of ISE

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: control group
Description: Control group Normal daily activities Usual daily activities